The Head and Neck Cancer
Drugs Market is expected to grow from $ 1.3 billion in
2017 to $ 2.28 billion by 2025, with a CAGR of 7.3% over the period 2018-2025.
The report includes the major
market players in the industry, such as AstraZeneca PLC, Eli Lilly and Company
(ARMO Biosciences), F. Hoffmann-La Roche Ltd. (Genentech, Inc.), Merck &
Co., Inc., Novartis AG, Bristol-Myers Squibb Company, Fortress Biotech, Inc.
(Checkpoint Therapeutics, Inc.), Immutep Limited, Merck KGaA (EMD Serono,
Inc.), and Pfizer Inc.
The market is segmented based
on drug class, sales channel, and geographical conditions. Based on drug
classes, the market is segmented into chemotherapy, immunotherapy, and targeted
therapies. The chemotherapy segment accounted for the largest share in 2017,
accounting for almost half of the overall market share. However, the
immunotherapy segment is expected to show the fastest CAGR of 12.1% during the
forecast period.
Based on sales channels, the
market is divided into hospital pharmacies, drug stores and retail pharmacies,
and online stores. The drugstore and retail pharmacy segments dominate the
market in terms of revenue and account for about 58% of total market share in
2017. However, the online store segment is projected to draw the fastest CAGR
of 10.2% until 2025.
Based on geography, the market
is divided into North America, Europe, Asia Pacific, Latin America, Middle
East, Africa (LAMEA). North America accounted for the largest share in 2017,
accounting for about half of the total market. However, the Asia Pacific region
is estimated to show the fastest CAGR of 9.7% during the forecast period.
No comments:
Post a Comment